• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Cornelia Zou

Articles by Cornelia Zou

CFDA focusing on quality, but fewer GMP inspections conducted in China

June 15, 2016
By Cornelia Zou and Bonnie Wang
HONG KONG – Aiming to address a perceived disparity in the quality of manufacturing of drugs for the China market, the CFDA is ramping up its focus on offshore drug manufacturers. The regulator last year stepped up the number of overseas good manufacturing practice (GMP) inspections it carried out, while domestically, it put more of the onus on companies to police themselves.
Read More

CFDA zeroes in on quality, but conducted fewer GMP inspections in China

June 14, 2016
By Cornelia Zou and Bonnie Wang
HONG KONG – Aiming to address a perceived disparity in the quality of manufacturing of drugs for the China market, the CFDA is ramping up its focus on offshore drug manufacturers. The regulator last year stepped up the number of overseas good manufacturing practice (GMP) inspections it carried out, while domestically, it put more of the onus on companies to police themselves.
Read More

Is China's precision medicine initiative a foreign affair?

June 10, 2016
By Cornelia Zou
HONG KONG – Although the government has set its sights on advancing personalized medicine in China, most of the existing gene-related technologies are still of foreign origin, so are some of the leading companies operating here. The question at the moment is whether development of precision medicine in the country is a domestic or foreign affair? And where will the huge amount of government funding in the space go?
Read More

With phase III success, Frontier Biotech seeks HIV drug approval

June 8, 2016
By Cornelia Zou
HONG KONG – China's Frontier Biotechnologies Co. Ltd. achieved positive results in a phase III study for the world's first injectable long-acting HIV drug. The weekly dose drug is targeted at Chinese patients via local development and manufacturing.
Read More

Is China's precision medicine initiative a foreign affair

June 8, 2016
By Cornelia Zou
HONG KONG – Although the government has set its sights on advancing personalized medicine in China, most of the existing gene-related technologies are still of foreign origin, so are some of the leading companies operating here. The question at the moment is whether development of precision medicine in the country is a domestic or foreign affair? And where will the huge amount of government funding in the space go?
Read More

Novartis' Shanghai R&D hub, adds to push for Chinese innovation

June 8, 2016
By Cornelia Zou
HONG KONG – Swiss pharmaceutical giant Novartis AG has officially launched its third global R&D hub, this one in China, where spirited debate over whether the country has true innovation or not is a daily occurrence.
Read More

With phase III success, Frontier Biotech seeks HIV drug approval

June 8, 2016
By Cornelia Zou
HONG KONG – China's Frontier Biotechnologies Co. Ltd. achieved positive results in a phase III study for the world's first injectable long-acting HIV drug. The weekly dose drug is targeted at Chinese patients via local development and manufacturing.
Read More

Novartis' Shanghai R&D hub, adds to push for Chinese innovation

June 7, 2016
By Cornelia Zou
HONG KONG – Swiss pharmaceutical giant Novartis AG has officially launched its third global R&D hub, this one in China, where spirited debate over whether the country has true innovation or not is a daily occurrence.
Read More

Israeli technology could make proton therapy more accessible

June 2, 2016
By Cornelia Zou

China’s Precision Medicine Cloud launched to foster $10B initiative

June 1, 2016
By Cornelia Zou
HONG KONG – Data infrastructure building has started quickly after China’s government announced plans to pour billions into the development of precision medicines. A group of leading companies in cloud computing, medical services and genomics have come together to provide the country with a platform essential to the future bloom of precision medicine in the country.
Read More
Previous 1 2 … 5 6 7 8 9 10 11 12 13 … 56 57 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 28, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 28, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 27, 2025
  • 3d rendering of bispecific antibodies

    Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody

    BioWorld
    Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...
  • Illustration of liver with DNA double helixes

    ASGCT 2025: Gene and cell therapies transform metabolic diseases

    BioWorld Science
    Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe